Background Significant racial differences have been observed in the incidence and clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) in the United States, but to the authors' knowledge it remains unclear whether genomic differences contribute to these disparities. METHODS To understand the influences of genetic ancestry on tumor genomic alterations, the authors estimated the genetic ancestry of 1001 previously described patients with DLBCL using unsupervised model‐based Admixture global ancestry analysis applied to exome sequencing data and examined the mutational profile of 150 DLBCL driver genes in tumors obtained from this cohort. Results Global ancestry prediction identified 619 patients with >90% European ancestry, 81 patients with >90% African ancestry, and 50 patients with >90% Asian ancestry. Compared with patients with DLBCL with European ancestry, patients with African ancestry were aged >10 years younger at the time of diagnosis and were more likely to present with B symptoms, elevated serum lactate dehydrogenase, extranodal disease, and advanced stage disease. Patients with African ancestry demonstrated worse overall survival compared with patients with European ancestry (median, 4.9 years vs 8.8 years; P = .04). Recurrent mutations of MLL2 (KMT2D), HIST1H1E, MYD88, BCL2, and PIM1 were found across all ancestry groups, suggesting shared mechanisms underlying tumor biology. The authors also identified 6 DLBCL driver genes that were more commonly mutated in patients with African ancestry compared with patients with European ancestry: ATM (21.0% vs 7.75%; P < .001), MGA (19.7% vs 5.33%; P < .001), SETD2 (17.3% vs 5.17%; P < .001), TET2 (12.3% vs 5.82%; P = .029), MLL3 (KMT2C) (11.1% vs 4.36%; P = .013), and DNMT3A (11.1% vs 4.52%; P = .016). Conclusions Distinct prevalence and patterns of mutation highlight an important difference in the mutational landscapes of DLBCL arising in different ancestry groups. To the authors' knowledge, the results of the current study provide the first‐ever characterization of genetic alterations among patients with African descent who are diagnosed with DLBCL.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is clinically heterogeneous. Integration of oral targeted therapies (OTTs) in the management of CLL has fundamentally altered CLL treatment pathways and improved outcomes for patients with CLL. We review the cost-effectiveness of OTTs in the treatment of CLL. We used MeSH (Medical Subject Heading) terms and keywords to search the National Library of Medicine online MEDLINE database (PubMed) for articles related to cost-effectiveness of OTTs in CLL care. Oral targeted therapies add considerable expense to the treatment of CLL for patients and the health care system. Cost-effectiveness analyses of OTTs are not uniform in their conclusions and depend on patient groups selected for analysis. Given the substantial increase in expense associated with integration of OTTs in CLL treatment, cost reduction methods are needed to ensure equitable access to novel therapies for all patients with CLL.
Significant differences have been observed in the incidence, age of onset, and clinical outcomes of diffuse large B-cell lymphoma (DLBCL) by race in the United States. However, it remains unclear what factors underlie these differences and whether genomic differences contribute to these disparities. We examined differences in baseline clinical characteristics for black and white patients with DLBCL and the relationships between race and outcomes. To understand the influences of genetic ancestry on tumor genomic alterations, in a recent paper (Lee et al, Cancer. 2020), we estimated the genetic ancestry of 1,001 previously described patients with DLBCL (Reddy et al, Cell. 2017) using unsupervised model-based Admixture global ancestry analysis applied to exome sequencing data and examined the mutational profile of 150 DLBCL driver genes. Global ancestry prediction identified 619 patients with >90% European ancestry, 81 patients with >90% African ancestry, and 50 patients with >90% Asian ancestry. Compared to DLBCL patients with >90% European ancestry, patients with >90% African ancestry were younger at the time of diagnosis and more commonly presented with B symptoms, abnormally elevated serum lactate dehydrogenase, extranodal disease, and advanced stage disease. All except younger age are poor prognostic factors in DLBCL. Patients with >90% African ancestry more commonly had mutations in six DLBCL driver genes compared with patients with >90% European ancestry: ATM (21.0% vs 7.75%; P < .001), MGA (19.7% vs 5.33%; P < .001), SETD2 (17.3% vs 5.17%; P < .001), TET2 (12.3% vs 5.82%; P = .029), KMT2C/MLL3 (11.1% vs 4.36%; P = .013), and DNMT3A (11.1% vs 4.52%; P = .016). Patients with >90% African ancestry also demonstrated worse overall survival compared with patients with >90% European ancestry (median, 4.9 years vs 8.8 years; P = .04). We further analyzed previously identified germline genetic loci associated with DLBCL susceptibility among predominantly European populations to evaluate local chromosomal ancestry in the African ancestry group. Additional comparisons of DLBCL subtype among individuals of African compared with European ancestry are being performed using the LymphGen probabilistic classification tool for genetic subtypes of DLBCL with therapeutic implications (Wright et al. Cancer Cell. 2020). The distinct patterns of clinical characteristics, somatic mutations, genetic alterations, and subtype distributions highlight important differences in the landscape of DLBCL arising in different ancestry groups. This characterization among patients with African ancestry who are diagnosed with DLBCL provides a roadmap for future studies in other malignancies for constructing multilevel models that address race and ancestry and a pathway for drug development in areas where these genomic alterations are found to be associated with worse clinical outcomes. Citation Format: Michelle J. Lee, Jean L. Koff, Michelle A.T. Hildebrandt, Jeffrey M. Switchenko, C. I. Jhaney, R. A. Harkins, Sharvil P. Patel, Sandeep S. Dave, Christopher R. Flowers. Mutational landscape of diffuse large B cell lymphoma in patients with genome-defined African ancestry [abstract]. In: Proceedings of the AACR Virtual Conference: Thirteenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2020 Oct 2-4. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(12 Suppl):Abstract nr PR14.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.